798 related articles for article (PubMed ID: 12006504)
61. [A clinical study of treating 120 cases of adult chronic myelocytic leukemia with imatinib mesylate].
Chen ZC; You Y; Zhu XM; Li QB; Li WM; Zou P
Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):1003-6. PubMed ID: 18478917
[TBL] [Abstract][Full Text] [Related]
62. Imatinib: a review of its use in chronic myeloid leukaemia.
Moen MD; McKeage K; Plosker GL; Siddiqui MA
Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
[TBL] [Abstract][Full Text] [Related]
63. [Monitoring of plasma concentration of imatinib mesylate in patients with chronic myeloid leukemia].
Chen C; Wang W; Xu CG; Hou M; Wang LQ; Liu CF; Song Q; Ji CY
Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):450-3. PubMed ID: 22213863
[TBL] [Abstract][Full Text] [Related]
64. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
Nicolini FE; Corm S; Lê QH; Sorel N; Hayette S; Bories D; Leguay T; Roy L; Giraudier S; Tulliez M; Facon T; Mahon FX; Cayuela JM; Rousselot P; Michallet M; Preudhomme C; Guilhot F; Roche-Lestienne C
Leukemia; 2006 Jun; 20(6):1061-6. PubMed ID: 16642048
[TBL] [Abstract][Full Text] [Related]
65. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
[TBL] [Abstract][Full Text] [Related]
66. [Origin of resistance to Imatinib mesylate: lessons learned from this experience].
Roche-Lestienne C; Mahon FX; Preudhomme C
Med Sci (Paris); 2004 Dec; 20(12):1125-30. PubMed ID: 15581468
[TBL] [Abstract][Full Text] [Related]
67. Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.
Vaidya S; Ghosh K; Vundinti BR
Eur J Haematol; 2011 Nov; 87(5):381-93. PubMed ID: 21815933
[TBL] [Abstract][Full Text] [Related]
68. [STI571: a new dimension in the treatment of chronic myeloid leukemia].
Somers JA; Shamelian SO; Löwenberg B; Ossenkoppele GJ; Cornelissen JJ
Ned Tijdschr Geneeskd; 2002 Jan; 146(3):128-32. PubMed ID: 11826673
[TBL] [Abstract][Full Text] [Related]
69. [Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib].
Huang XJ; Hu JD; Li JY; Jin J; Meng FY; Shen ZX; Liu T; Wu DP; Wang JM; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):889-95. PubMed ID: 23363742
[TBL] [Abstract][Full Text] [Related]
70. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Olavarria E; Ottmann OG; Deininger M; Clark RE; Bandini G; Byrne J; Lipton J; Vitek A; Michallet M; Siegert W; Ullmann A; Wassmann B; Niederwieser D; Fischer T;
Leukemia; 2003 Sep; 17(9):1707-12. PubMed ID: 12970768
[TBL] [Abstract][Full Text] [Related]
71. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
Teng JF; Mabasa VH; Ensom MH
Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
[TBL] [Abstract][Full Text] [Related]
72. [Imatinib therapy for patients with chronic myelogenous leukemia].
Kawai Y; Ueda T
Nihon Rinsho; 2004 Jul; 62(7):1325-31. PubMed ID: 15283151
[TBL] [Abstract][Full Text] [Related]
73. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
74. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.
Albajar M; Gómez-Casares MT; Llorca J; Mauleon I; Vaqué JP; Acosta JC; Bermúdez A; Donato N; Delgado MD; León J
Mol Cancer Res; 2011 May; 9(5):564-76. PubMed ID: 21460180
[TBL] [Abstract][Full Text] [Related]
75. [Signal transduction inhibitor--STI571--a new treatment for chronic myeloid leukemia (CML), which opens a new targeted approach to cancer therapy].
Nadav L; Eldor A
Harefuah; 2002 Feb; 141(2):158-62, 222. PubMed ID: 11905088
[TBL] [Abstract][Full Text] [Related]
76. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).
Gordon JK; Magid SK; Maki RG; Fleisher M; Berman E
Leuk Res; 2010 Jun; 34(6):827-9. PubMed ID: 19963273
[TBL] [Abstract][Full Text] [Related]
77. Pattern of pediatric chronic myeloid leukemia in Sudan and hematological response to imatinib.
Alkhatib MA
Pediatr Hematol Oncol; 2011 Mar; 28(2):100-5. PubMed ID: 21083363
[TBL] [Abstract][Full Text] [Related]
78. [Results up to now of administration of STI-571 (Glivec) in recurrence after allogenic and autologous stem cell transplantation in chronic myeloid leukemia].
Fischer T
Med Klin (Munich); 2002 Jan; 97 Suppl 1():22-7. PubMed ID: 11831068
[TBL] [Abstract][Full Text] [Related]
79. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Zonder JA; Schiffer CA
Curr Hematol Malig Rep; 2006 Sep; 1(3):141-51. PubMed ID: 20425345
[TBL] [Abstract][Full Text] [Related]
80. [Chronic myelogenous leukemia].
Ohnishi K
Gan To Kagaku Ryoho; 2001 Sep; 28(9):1199-205. PubMed ID: 11579630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
